(Nasdaq: PDSB) Tops Wednesday's Watchlist (5 Potential Catalysts - Strong Average Analyst Target)

A clinical‑stage player is reshaping how cancer

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (Nasdaq: PDSB) Tops Wednesday's Watchlist (5 Potential Catalysts - Strong Average Analyst Target) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* January 27th Greetings, Friend! A clinical‑stage player is reshaping how cancer and infectious diseases are tackled, leveraging a distinct immunotherapy strategy that stands apart from conventional approaches. Rather than relying solely on traditional treatments, it focuses on boosting the body’s own capacity to recognize and eliminate diseased cells, and this has translated into notable momentum across several ongoing trials. The initial readouts suggest it may be capable of driving durable responses, including in some of the toughest indications. Backed by committed leadership and an expanding base of patents, the company is beginning to draw notice among scientific and medical circles. Meanwhile, an average analyst price target of $9 implies the potential for triple‑digit update, suggesting this lesser‑known Nasdaq profile could soon attract far more attention: PDS Biotechnology Corporation (Nasdaq: PDSB) PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The Company has initiated a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech’s lead investigational targeted immunotherapy PDS0101 (Versamune® HPV) is being developed in combination with a standard-of-care immune checkpoint inhibitor, and in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor. Company Breakdown - PDS Biotechnology Corp. (Nasdaq: PDSB) PDS Biotech was established with the goal of harnessing the power of T cells to address some of the most devastating illnesses of modern times. While many companies have attempted to leverage the body’s immune system to induce a strong T cell response, most have been unsuccessful in overcoming the tumor’s ability to defend itself against the immune system and in producing the right type and quantity of potent tumor-infiltrating T cells needed to execute a targeted attack. PDS Biotech’s proprietary targeted technologies are designed to deliver IL-12 into the tumor’s inner environment to suppress the tumor’s defenses against T cells while simultaneously generating a potent, targeted T cell attack on the cancer. When paired with proprietary tumor-associated proteins called antigens, PDS Biotech’s Versamune® platform has been shown to promote the induction of the right type and quantity of potent tumor-infiltrating killer and helper T cells that specifically recognize the tumor antigen. PDS01ADC, the company’s novel investigational tumor-targeting IL-12 fused antibody drug conjugate, when used with Versamune®, overcomes tumor-induced suppression of the immune system. This proprietary combination also promotes enhanced infiltration and expansion of T cells within the tumor, leading to more effective immunotherapy. In addition, PDS Biotech’s Infectimune® platform is being applied in the development of novel investigational T cell- and antibody-inducing preventive vaccines. PDS Biotech is committed to developing novel investigational immunotherapies based on its T cell-stimulating platforms to save and improve the lives of patients worldwide: Versamune®-based T-cell Stimulating Immunotherapies (TSI): Developed to provide a targeted attack against tumor-associated proteins called antigens. Versamune®-based T-cell Stimulating Immunotherapy (TSI) plus PDS01ADC: A novel investigational tumor-targeting IL-12 fused antibody drug conjugate that targets the tumor microenvironment to suppress the tumor’s defenses against the immune system and promotes enhanced infiltration and expansion of T cells within the tumor, with the goal of treating recurrent and/or metastatic (R/M) cancers with poor survival prognosis. PDS Biotech's Pipeline Find sources and more here: PDSB Website. PDSB Presentation. ----- 5 Key Potential Catalysts On Display For (Nasdaq: PSDB) 1.) An Average Analyst Target May Suggest Potential Triple- Digit Upside (Over 750%). Over at TipRanks, the website is tracking several analysts and their judgements of PDSB. In fact, at close on Tuesday, the site was suggesting 2 analyst targets averaging $9.00. That $9.00 average target may signal PDSB to be undervalued with a potential upside over 750%. 2.) Strengthened Intellectual Property Foundation Supporting Long Term PDS0101 Value. The new U.S. patent allowance for PDS0101 will secure broad composition and method-of-use coverage for PDS Biotech’s lead immunotherapy, reinforcing the strategic value of the Versamune platform and PDS0101 in late-stage development. Combined with anticipated biologics exclusivity, this protection is expected to extend market opp. for more than 20 years, supporting durable commercial potential. The patent builds on an extensive global IP estate across major markets, further de‑risking the asset as PDS0101 advances in Phase 3 development for HPV16‑positive head and neck cancer. 3.) Regulatory Alignment Accelerates Path Toward PDS0101 Commercialization. FDA alignment on using progression‑free survival as the primary endpoint in the Phase 3 VERSATILE‑003 trial gives PDS Biotech a clearer and potentially faster route to accelerated approval for PDS0101 in HPV16‑positive recurrent or metastatic head and neck cancer. Progression‑free survival can be read out earlier with strong statistical power, potentially shortening trial duration while median overall survival and safety remain in place for full approval, preserving robust standards. The constructive Type C meeting and supportive VERSATILE‑002 data underscore productive FDA engagement and strengthen confidence in PDS0101’s regulatory trajectory. 4.) Global Patent Expansion Strengthens Long Term PDS0101 Commercial Opp. Grant of a new composition‑of‑matter patent for PDS0101 in Japan broadens PDS Biotech’s global intellectual property position, adding wide‑ranging composition and methods‑of‑use protection in another key oncology market. This patent complements existing protections in the United States, China, Australia, Hong Kong, and prior Japanese patents, creating a robust global IP wall around PDS0101. Together with expected U.S. biologics exclusivity, these rights extend patent and market protection into the 2040s, supporting long‑term value as PDS0101 progresses in Phase 3 evaluation for HPV16‑positive head and neck cancer. 5.) Compelling Translational Evidence Supports PDS0101 And PDS01ADC Clinical Promise. New translational data presented at SITC 2025 show that multiple immune biomarkers can predict clinical activity of PDS0101 combinations, providing powerful tools to optimize patient selection and guide future trials. PDS01ADC was shown to reprogram natural killer cells toward highly active, cancer‑killing phenotypes while promoting self‑renewing, stem‑like and memory T cells capable of durable anti‑tumor responses, reinforcing its potential as a long‑lasting immunotherapy. These findings validate PDS Biotech’s platforms mechanistically and bolster confidence in advancing PDS0101 and PDS01ADC toward future regulatory and commercial milestones. ----- We're officially kicking-off coverage on PDS Biotechnology Corporation (Nasdaq: PDSB). Be on the lookout for updates coming soon. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 01/27/2026 and ending on 01/28/2026 to publicly disseminate information about (PDSB:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (PDSB:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/pdsb-p1cqr/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice